• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
HE Yu, TIAN Hong, DAI Xin, YAO Wenbing, GAO Xiangdong. Immunogenicity of HER2 vaccine containing p-nitrophenylalanine[J]. Journal of China Pharmaceutical University, 2018, 49(3): 369-375. DOI: 10.11665/j.issn.1000-5048.20180317
Citation: HE Yu, TIAN Hong, DAI Xin, YAO Wenbing, GAO Xiangdong. Immunogenicity of HER2 vaccine containing p-nitrophenylalanine[J]. Journal of China Pharmaceutical University, 2018, 49(3): 369-375. DOI: 10.11665/j.issn.1000-5048.20180317
shu

Immunogenicity of HER2 vaccine containing p-nitrophenylalanine

More Information
    Graphical Abstract
    • Abstract
  • In order to delete the immune tolerance of self-protein HER2 and produce an efficient immune response, the genetic code expansion technique was employed to introduce the immunogenic amino acid p-nitrophenylalanine into the position 5, 26 and 79 of the HER2 fragment and HER2 mutants containing p-nitrophenylalanine were obtained. Prototype and mutant HER2 molecules with a purity of more than 95% were obtained through a nickel affinity column. Immunogenicity analysis of the HER2 vaccine showed that pNO2Phe79HER2 was able to produce high titer cross-reactive antibodies in C57BL/6 mice and that the mouse antisera could recognize SKBR-3 cells with intact HER2 receptor extracellular domain and cleave HER2 highly expressed HER2+B16F10 cells through ADCC effect. These findings suggested that pNO2Phe79HER2 which incorporates p-nitrophenylalanine could be used as a tumor vaccine candidate targeting HER2.
    • FullText(HTML)
    • References (17)
  • [1]
    Liu Y,el-Ashry D,Chen D,et al.MCF-7 breast cancer cells ove-rexpressing transfected cerbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo[J].Breast Cancer Res Treat,1995,34(2):97-117.
    [2]
    Tsang R,Finn R.Beyond trastuzumab:novel therapeutic strategies in HER2-positive metastatic breast cancer [J].Br J Cancer,2012,106(1):6-13.
    [3]
    De Santes K,Slamon D,Anderson SK,et al.Radiolabeled antibody targeting of the HER-2/neu oncoprotein [J].Cancer Res,1992,52(7):1916-1923.
    [4]
    Spector NL,Xia W,Burris H,et al.Study of the biologic effects of lapatinib,a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies [J].J Clin Oncol,2005,23(11):2502-2512.
    [5]
    Earl HM,Vallier AL,Dunn J,et al.Trastuzumab-associated cardiac events in the Persephone trial [J].Br J Cancer,2016,115(12):1462-1470.
    [6]
    Eryilmaz A,Demirci B,Gunel C,et al.Evaluation of lapatinib and trastuzumab for ototoxic effects [J].J Int Adv Otol,2015,11(3):207-211.
    [7]
    Spector NL,Xia W,Burris H,et al.Study of the biologic effects of lapatinib,a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies [J].J Clin Oncol,2005,23(11):2502-2512.
    [8]
    Costa RLB,Soliman H,Czerniecki BJ.The clinical development of vaccines for HER2+ breast cancer:current landscape and future perspectives [J].Cancer Treat Rev,2017,61:107-115.
    [9]
    Tabi Z,Man S.Challenges for cancer vaccine development [J].Adv Drug Deliv Rev,2006,58(8):902-915.
    [10]
    Dalgleish AG.Therapeutic cancer vaccines:why so few randomised phase III studies reflect the initial optimism of phase II studies [J].Vaccine,2011,29(47):8501-8505.
    [11]
    Grunewald J,Hunt GS,Dong L,et al.Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids [J].Proc Natl Acad Sci U S A,2009,106(11):4337-4342.
    [12]
    Dai HT,Tian H,Huang J,et al.Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice [J].J China Pharm Univ(中国药科大学学报),2017,48(4):483-489.
    [13]
    Kessel C,Nandakumar KS,Peters FB,et al.A single functional group substitution in C5a breaks B cell and T cell tolerance and protects against experimental arthritis [J].Arthritis Rheumatol,2014,66(3):610-621.
    [14]
    Cai D,Tian H,Yao WB.Molecular dynamics simulation and analysis of BAFF which is incorporated with p-nitro-L-phenylalanine[J].J China Pharm Univ(中国药科大学学报),2017,48(2):227-232.
    [15]
    Gauba V, Grunewald J, Gorney V, et al. Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids [J].Proc Natl Acad Sci U S A,2011,108(31):12821-12826.
    [16]
    Kageyama S, Kitano S, Hirayama M, et al. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel [J].Cancer Sci,2008,99(3):601-607.
    [17]
    Hardy LL, Wick DA, Webb JR. Conversion of tyrosine to the inflammation-associated analog 3′-nitrotyrosine at either TCR- or MHC-contact positions can profoundly affect recognition of the MHC class I-restricted epitope of lymphocytic choriomeningitis virus glycoprotein 33 by CD8 T cells [J].J Immunol,2008,180(9):5956-5962.
    • Related Articles

  • Related Articles

    [1]MA Wenxuan, HAN Yuhong, LIN Ang, ZHAO Weijun. A comparative analysis of vaccine immunity induced by heterologous booster with Ad5-nCoV via different routes of administration[J]. Journal of China Pharmaceutical University, 2024, 55(1): 137-146. DOI: 10.11665/j.issn.1000-5048.2024011701
    [2]CHEN Hongmei, KANG Yanliang, LIU Li, YAO Wenbing, TIAN Hong. Effects of different immunogenic amino acids in PD-L1 vaccine on the differentiation of T cell subsets[J]. Journal of China Pharmaceutical University, 2020, 51(3): 349-356. DOI: 10.11665/j.issn.1000-5048.20200313
    [3]JIANG Liangliang, JIANG Tao, LUO Jianhua, YAO Wenbing, TIAN Hong. A novel human immune system mice model for assessing the immunogenicity of cancer vaccines[J]. Journal of China Pharmaceutical University, 2019, 50(6): 734-742. DOI: 10.11665/j.issn.1000-5048.20190615
    [4]NING Hongyu, JIANG Tao, ZHANG Rui, HE Yu, YAO Wenbing, TIAN Hong. Effects of immunogenic HER2 on the differentiation of T-cell in mouse[J]. Journal of China Pharmaceutical University, 2018, 49(1): 102-108. DOI: 10.11665/j.issn.1000-5048.20180115
    [5]DAI Huiteng, TIAN Hong, HUANG Jie, CHEN Chao, CAI Di, GAO Xiangdong, YAO Wenbing. Protective effects of p-nitrophenylalanine-containing BAFF vaccine on lupus nephritis model mice[J]. Journal of China Pharmaceutical University, 2017, 48(4): 483-489. DOI: 10.11665/j.issn.1000-5048.20170414
    [6]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [7]Stability of influenza vaccine liposome powder[J]. Journal of China Pharmaceutical University, 2010, 41(4): 360-362.
    [8]LU Wei-dong, LIN Yi-ju, DAI Yun-bo, YANG Xuan-xiang, MA Bo. Preparation and immunogenicity of influenza vaccine lyophilized liposomes[J]. Journal of China Pharmaceutical University, 2009, 40(3): 218-221.
    [10]Study on the Immunogenity of Antigen and Antigenic Epitope Displayed by Phage Display of pIII and pVIII[J]. Journal of China Pharmaceutical University, 2004, (6): 100-105.

Catalog

    Get Citation
    PDF
    XML
    Article views (802) PDF downloads (1152) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：326347

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return